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Abstract
Context—Annual ultrasound (US) may detect small, node-negative breast cancers not seen on
mammography (M). MRI may depict additional breast cancers beyond mammography and
ultrasound (M+US).
Objective—Determine supplemental cancer detection yield of ultrasound and MRI in women at
elevated risk for breast cancer.
Design, Setting, Participants—From April 2004 to February 2006, 2809 women at 21 sites
with elevated cancer risk and dense breasts consented to three annual independent screens with
mammography and ultrasound in randomized order. After 3 rounds of mammography and US
screening, 703 women from 14 sites consented to a single MRI.
Main Outcome Measures—Cancer detection rate (yield), sensitivity, specificity, positive
predictive value of biopsies performed (PPV3 – rate of malignancy among cases positive on
screening, who actually underwent biopsy), interval cancer rate. The diagnosis of breast cancer
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was based on a biopsy showing in situ or infiltrating ductal carcinoma or infiltrating lobular
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carcinoma in the breast or axillary lymph nodes. Reference standard was defined as a combination
of pathology and 12-month follow-up and was available for 2662 women (7473 M+US screens)
and 612 MRI participants.
Results—The 2662 patients underwent 7473 mammograms and US, with 110 women having
111 breast cancers detected, of which 33 were detected on mammography only, 32 on US only, 26
on both mammography and US, and 9 on MRI after mammography and US. Eleven were not
detected by any imaging modality. Supplemental incidence-screening US identified 3.7 cancers
per 1000 women-screens (95% CI 2.1 to 5.8, p<.001). Sensitivity, specificity, and PPV3 for M
+US were 57/75 (0.76, 95% CI 0.65 to 0.85), 3987/4739 (0.84, 95% CI 0.83 to 0.85), and 55/339
(0.16, 95% CI 0.12 to 0.21); and for mammography alone 39/75 (0.52, 95% CI 0.40 to 0.64),
4325/4739 (0.91,95% 0.90 to 0.92), and 37/97 (0.38, 95% CI 0.28 to 0.49) (p<.001 all
comparisons). Of 612 analyzable MRI participants, 16 (2.6%) had breast cancer diagnosed.
Supplemental yield of MRI was 14.7 per 1000 (95% CI 3.5 to 25.9, p=.004). Sensitivity,
specificity, and PPV3 for MRI+M+US were 16/16 (1.00, 95% CI 0.79 to 1.00), 390/596 (0.65,
95% CI 0.61 to 0.69), and 15/81 (0.19, 95% CI 0.11 to 0.29); and for M+US 7/16 (0.44, 95% CI
0.20 to 0.70, p=.004), 503/596 (0.84, 95% CI 0.81 to 0.87, p <.001), and 7/38 (0.18, 95% CI 0.08
to 0.34, p= .98) for M+US. Number of screens needed to detect one cancer was 127(95%CI 99 to
167) for mammography; 234(95%CI 173 to 345) for supplemental ultrasound, and 68 (95%CI 39
to 286) for MRI after negative M+US.
Conclusions—The addition of screening ultrasound or MRI to mammography in women at
increased risk of breast cancer resulted in a higher cancer detection yield but also an increase in
false positive findings.
INTRODUCTION
Six previous single-center studies1–6 and three multicenter trials7–9 have shown
supplemental screening breast ultrasound significantly increases detection of node-negative
invasive breast cancer in women with mammographically dense breast tissue on the first,
prevalence screen, consistently increasing cancer detection (yield) by 3.5 per 1000 in single-
center studies and 4.2 to 4.4 per 1000 in multicenter trials. The vast majority of cancers seen
only on ultrasound have been node-negative invasive breast cancers. Until now, it was
unclear whether or not there was a detection benefit to continuing ultrasound screening
annually (i.e. incidence screening).
A substantial majority of ACRIN 6666 participants were at intermediate risk for breast
cancer, with over half having personal history of breast cancer (PHBC).7 While there was
evidence from prior studies10–13 that MRI provided considerable detection benefit even after
combined ultrasound and mammography in high-risk women, the combination of ultrasound
and mammography might still identify the vast majority of cancers when they are node
negative, at much lower cost to the health care system than MRI, particularly in screening
women with a lower prevalence of disease. A substudy of ACRIN 6666 participants was




Participants were asymptomatic women with heterogeneously dense or extremely dense
breast tissue14 and at least one other risk factor for breast cancer (Table 1) who presented for
routine annual mammography. Race and ethnic group were self-assigned based on pre-
assigned fixed categories.
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Each participant underwent mammographic and physician-performed ultrasonographic
screening examinations in randomized order, with the interpreting radiologist for each
examination masked to results of the other study, at 0 months (screen 1), 12 months (screen
2), and 24 months (screen 3). The randomization process has been previously described,7
and initial randomization order was maintained for subsequent screening rounds. If
recommendation from either screening test was other than routine annual screening, the test
was considered positive and a qualified site investigator then recorded an integrated
interpretation by reviewing study mammogram and ultrasound together, and clinical
management was based on integrated interpretation. If both modalities recommended routine
annual follow-up, no integration was performed. Cancers positive only on a given modality
refers to those not visible on any other modality. Sensitivity of a modality alone refers to the
number of cancers that would have been detected if only that modality had been used, and
includes some cancers that were also visible on the other modality.
To be eligible for the MRI substudy, women had to have completed the third round of
annual screening ultrasound and mammography per protocol7 and undergo contrast-
enhanced breast MRI within 8 weeks of the 24 month (third) screening mammogram.
Interpretation of each of screening mammography, screening US, and MRI was blinded to
results of the other examinations. A separate integrated breast-level interpretation across all
modalities (mammography, ultrasound, MRI) was then performed which determined clinical
management. We have previously reported on the slightly greater risk and younger age of
women accepting vs. declining MRI.15 Women enrolled at sites in the MRI substudy were
less likely to have PHBC; no other systematic differences were noted across sites.
Web-based data capture and quality monitoring were conducted by the ACRIN biostatistics
and data management center. The study was HIPAA-compliant and received institutional
review board approval from all participating sites, ACRIN and National Cancer Institute
Cancer Imaging Program approval, and data and safety monitoring committee review every
six months.
Participants
Among the 21 sites, 2809 women were recruited between April 2004 and February 2006, of
whom 2725 were eligible (Figure 1). Women aged at least 25 years presenting for routine
mammography were eligible to participate if they met study definitions of elevated risk
(Table 1) and had heterogeneously dense or extremely dense parenchyma14 in at least one
quadrant, either by prior mammography report or review of prior mammograms. Women
were excluded if they were pregnant or lactating, had known metastatic disease, signs or
symptoms of breast disease, breast surgery within prior 12 months, or breast implants. For
the MRI substudy, women also could not have contraindications to MRI [pacemaker,
aneurysm clip, other metallic implant, weight > 300 lb, or renal impairment (glomerular
filtration rate of <30 mL/min/1.73 m2 or dialysis regimen)]. Participants provided written
informed consent at their initial visit and again for the MRI substudy (when applicable).
Screening methods are detailed in the online supplement. Expanded 7-point BI-
RADS27,29,30 assessment scale was used: 1, negative; 2, benign; 3, probably benign; 4a, low
suspicion; 4b, intermediate suspicion; 4c, moderate suspicion; and 5, highly suggestive of
malignancy.
Reference Standard
Reference standard was the most severe of biopsy results within 365 days of mammographic
screening and/or clinical follow-up at one year. Each mammographic screen was targeted
365 days after the previous mammographic screening. A complete examination of all study
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breasts performed more than 11 full months after the previous screen was considered the
next annual screen; only 88/7473 (1.2%) visits occurred before 11 months. The absence of a
known diagnosis of cancer on participant interview, review of medical records, or both, at
least 11 full months (330 days) after mammographic screening, was considered disease
negative, as were 7 cases of prophylactic mastectomies with no evidence of cancer at
pathology. Biopsy results showing breast cancer (in situ or infiltrating ductal carcinoma or
infiltrating lobular carcinoma) in the breast or axillary lymph nodes were considered disease
positive.
Statistical Methods
The primary unit of analysis was the participant. Participant’s BI-RADS score was derived
as the maximum breast level BI-RADS or the score from the cancer side when only one
breast had cancer. In keeping with planned revisions to BI-RADS (Edward A. Sickles, MD,
Professor of Radiology, University of California, San Francisco, personal written
communication 11/29/09), a screening BI-RADS assessment score of 3, 4a, 4b, 4c, or 5 was
considered test positive, provided the recommendation was for other than routine screening.
This differs from the definition of test positive used in our initial publication of the first
screen wherein an assessment of 4a or higher was considered test positive29: results of the
first screen have been reanalyzed and included herein. For a participant diagnosed with
cancer, the breast(s) with cancer were excluded from analysis for the next annual screen.
The cancer detection rate (yield, i.e., the proportion of women with a positive screen test and
positive reference standard), sensitivity, specificity, recall rate, PPV1 (malignancy rate
among cases positive on screening), short-term follow-up rate, biopsy rate and AUC (area
under the empirical ROC curve using BI-RADS scores) were reported. PPV3 is defined as
rate of malignancy among cases positive on screening who underwent biopsy of the same
lesion.14 Interval cancers were defined as those diagnosed because of a clinical abnormality
such as a lump, skin thickening, or pathologic nipple discharge, in the interval between
prescribed screenings (i.e. less than 365 days after the last screening mammogram).
Single-year estimates of yield, sensitivity, specificity, recall rate, PPV1, short-term follow-
up rate, biopsy rate and PPV3, were determined as simple proportions with exact 95% CIs
(Clopper-Pearson).16 The 95% CIs for differences in yield, sensitivity, specificity, recall
rate, short-term follow-up rate and biopsy rate were calculated per Fleiss et al17 and p-values
for the above comparisons were based on McNemar’s test statistic. The 95% CIs and p-
values for differences in PPV1 and PPV3 were calculated using bootstrap resampling
method18. All inferences for incidence screens were based on bootstrap resampling method.
Estimates, 95% CIs and P-values related to AUC were derived by using method of Delong
et al19 for empirical ROC curves. Results in participants with PHBC were compared to those
without by the bootstrap method. All p-values were reported as two-sided, with 0.05 set as
threshold for significance. All analyses were implemented in SAS 9.2 (Cary, NC).
RESULTS
Participant Demographic Information
There were 2659, 2493, and 2321 eligible women with reference standard for the first,
second, and third annual mammogram and ultrasound screens respectively (Figure 1, Table
1). Participant demographics at enrollment were previously reported.7 Median age at
enrollment was 55 years (range 25–91). Approximately 29% of women were under age 50 at
enrollment and 23% were premenopausal (Table 1). Nearly 54% of women had PHBC.
Median age of 612 MRI participants was 57 years (range 27–87); 21% were under age 50 at
scan, 25% were premenopausal, and 45% had PHBC.
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A total of 110 participants were diagnosed with breast cancer over three years of study, with
one woman diagnosed by mammography in year one again diagnosed in the contralateral
breast in year 3 (by MRI only) and counted as separate events, i.e. total of 111 participant-
cancer events. Of 111 diagnoses, 89 (80%) were invasive (Table 2). Fifty-nine of 111 (53%)
were seen on mammography, including 33 (30%) seen only on mammography; 32 (29%)
additional only on US; 9 (8%) only on MRI after both mammography and US; and 11 (10%)
not seen on imaging. Of 32 cancers seen only on US, 30 (94%) were invasive, with median
size 10 mm (range 2–40), and 26/27 (96%) of those staged were node negative.
A total of 16/612 (2.6%) MRI participants were diagnosed with breast cancer, with 12/16
(75%) invasive. 9/16 (56%) were seen only on MRI after negative mammography and US:
8/9 (89%) were invasive, with median size 8.5 mm (range 1–25), and all 7 with staging were
node negative (Table 2). Two invasive cancers detected by US and not mammography in the
MRI substudy were also seen on MRI.
Supplemental Cancer Detection Yield
Supplemental US increased cancer detection with each annual screen beyond that of
mammography, adding detection of 5.3 cancers per 1000 women in year one (95%CI 2.1 to
8.4; p<.001 vs. mammography alone); 3.7 per 1000 per year in years two and three (95%CI
2.1 to 5.8, p<.001 vs. mammography alone) (Table 3); and averaging 4.3 per 1000 for each
of three rounds of annual screening. Addition of MRI increased cancer detection, with
supplemental cancer detection yield of 14.7 per 1000 women (95%CI 3.5 to 25.9, p=.004 vs.
M+US) (Table 4). Number of screens needed to detect one cancer was 127(95%CI 99 to
167) for mammography; 234(95%CI 173 to 345) for supplemental ultrasound and 68
(95%CI 39 to 286) for MRI after negative M+US.
Sensitivity, Specificity, and AUC
Sensitivity of combined mammography and US was 57/75(0.76, 95%CI 0.65 to 0.85) for
combined screens two and three, higher than mammography alone [39/75(0.52, 95%CI 0.40
to 0.64), p<.001]. Specificity of combined mammography and US was 3987/4739 (0.84,
95%CI 0.83 to 0.85) for incidence screens, lower than specificity of mammography alone
[4325/4739 (0.91, 95%CI 0.90 to 0.92), p<.001] (Table 3).
For 612 MRI participants, sensitivity increased from 7/16(0.44, 95%CI 0.20 to 0.70) with
combined mammography and ultrasound to 16/16(1.00, 95%CI 0.79 to 1.00) with addition
of MRI(p=.004). Specificity was reduced to 390/596(0.65, 95%CI 0.61 to 0.69) after MRI,
compared to combined M+US at 503/596(0.84, 95%CI 0.81 to 0.87, p <.001) (Table 4).
Overall AUC increased in each year when US was added to mammography (Table 3).
Adding MRI lowered apparent performance of M+US since more cancers were identified by
MRI (Table 4).
Additional Biopsies and PPV3
PPV3 of combined mammography and US was 31/272(0.11, 95%CI 0.08 to 0.16) for year 1
and 55/339(0.16, 95%CI 0.12 to 0.21) for incidence screens (years two and three combined),
These values were significantly lower than those of mammography alone (19/65 [0.29,
95%CI 0.19 to 0.42] and 37/97[0.38, 95%CI 0.28 to 0.49] respectively, p<.001 for both)
(Table 3). Percentage of women undergoing biopsy after mammography and US decreased
from 272/2659 (10.2%, 95%CI 9.1 to 11.4%) in year 1 to 339/4814 (7.0%, 95%CI 6.3 to
7.8%) for incidence screens (p<.001). The biopsy rates after mammography alone were
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65/2659 (2.4%, 95%CI 1.9 to 3.1%) in year 1 and 97/4814 (2.0%, 95%CI 1.6 to 2.5%) for
incidence screens.
For 612 MRI participants, rate of biopsy after full workup of M+US was 38/612(6.2%,
95%CI 4.4 to 8.4%), which increased to 81/612(13.2%, 95% CI10.7 to 16.2%) with addition
of MRI (p<.001). PPV3 after M+US was 7/38(0.18, 95%CI 0.08 to 0.34) and with addition
of MRI was 15/81(0.19, 95%CI 0.11 to 0.29, p=.98) (Table 4).
Interval Cancers
Of 20 women with cancer not seen on either mammography or US in three annual rounds, 9
were among the 612 participants who also had MRI screening in year three, with cancer
detected on MRI. Another 9 cancers were identified because of clinical abnormalities in
interval between screens (interval cancer rate 8.1%): two had clinical findings in year one;
four in year two; and three in year three. One participant was found to have high-grade
DCIS because of off-study computer-assisted detection applied to mammogram (revealing
calcifications) after year 3 interpretation had been recorded. One participant with BRCA-1
mutation had MRI off study six months after the third screen and was found to have a 7 mm
node-negative grade III IDC.
Women with Personal History of Breast Cancer (PHBC)
A total of 1426/2659(54%) of participants had PHBC at study entry and underwent 4010
screens; 59/1426 (4.1%) were diagnosed with cancer (28 only ipsilateral and 29 only
contralateral to the original cancer; 2 bilateral). Supplemental yield of US was the same in
women with PHBC and in women without PHBC (online Table 5A), as was the absolute
increase in sensitivity due to added ultrasound. Supplemental US was less likely to prompt
unnecessary recall or biopsy in women with PHBC than those without (online Table 5A). .
The supplemental yield of MRI in women with or without PHBC in MR substudy is detailed
online (online Table 5B). Supplemental MRI was less likely to prompt unnecessary recall or
biopsy in women with PHBC than those without (online Table 5B).
DISCUSSION
In this study, annual supplemental incidence screening ultrasound detected an additional 3.7
cancers per 1000 women per year screened beyond mammography alone. The majority of
cancers seen only on US were node-negative invasive cancers; invasive lobular carcinoma
and low-grade invasive ductal carcinoma were overrepresented among such cancers.
One of the major concerns about screening is the harm of extra testing and biopsies for
women who do not have cancer.20 As has been observed with mammography21 and
MRI,11,22–24 the risk of false positives decreased significantly with annual screening
ultrasound in this study compared to the first screen. However, there still remained a
substantial rate of biopsies prompted only by incidence screening ultrasound, averaging
5.0% (242/4814) of women, with only 7.4% (18/242) of those biopsied only due to
ultrasound found to have cancer.
In a separate analysis of ACRIN 6666 participants, MRI was significantly less tolerable than
mammography or ultrasound.25 Only 58% of ACRIN 6666 participants offered a screening
MRI at no out-of-pocket cost accepted the invitation.15 These barriers are in addition to high
costs of MRI equipment, contrast, and examination, as well as high rates of induced testing
including biopsy.
Contrast-enhanced MRI has been recommended for supplemental screening of women at
high risk for breast cancer, defined as those women with a lifetime risk of 20 to 25% or
Berg et al. Page 7













greater based on family history or prior mantle radiation to the chest.26 Across nine series,
the supplemental yield of MRI after mammography in high-risk women was 11 per 1000
(reviewed in 27), and was 14 per 1000 among the subset who also had screening
ultrasound.11–13,24 Similar results were observed in this study of women who were mostly at
intermediate risk for breast cancer.
Fewer studies have evaluated MRI in women at intermediate risk, including women with
PHBC, prior atypical biopsy or lobular carcinoma in situ (LCIS), intermediate family history
of breast cancer (lifetime risk of 15–20% per the ACS guidelines26), or women whose only
risk factor is dense breasts. Recent studies collectively suggest that supplemental MRI
screening may be reasonable for women with PHBC and also found false positives to be less
frequent than in women with a family history of breast cancer.28–30
For high-risk women unable to undergo MRI,15 and for intermediate-risk women with dense
breasts, including those with PHBC, this study supports the use of supplemental screening
with ultrasound in addition to mammography. With either MRI or US, the risks of false
positives, including unnecessary biopsies, were lower for supplemental screening in women
with PHBC than in women without. The outcomes in terms of staging, node-positive
disease, and interval cancer rates achieved in this study after three years of programmatic
screening with both ultrasound and mammography were comparable to benchmarks from
studies which included MRI.10–13,24
If screening ultrasound were to be adopted for women with dense breasts who are not
candidates for MRI, there would be obstacles to its implementation. These include the
availability of only one current procedural terminology (CPT) code, 76645, for breast
ultrasound, with low reimbursement (2010 Medicare reimbursement averaged a global fee
of $89.85 to $91.83,31 which does not cover the costs of physicians performing and
interpreting a thorough screening examination). While supplemental cancer detection rates
with technologist-performed screening US were similar to physician-performed US in one
series,4 there remains a shortage of qualified breast US technologists.
There are a few limitations to this study. Additional node-negative invasive cancers were
found by adding screening ultrasound to mammography in each incidence screen, and
increasing detection of such cancers correlates with mortality reduction;32 however, we did
not have a control group with no ultrasound performed in which to compare clinical
outcomes, and mortality was not assessed. In Japan, the ongoing J-START trial of biennial
mammography, with or without technologist-performed screening ultrasound, will follow
outcomes to mortality reduction.33 We only performed a single screening MRI, and false
positives would be expected to decrease in subsequent years.11,22 Not all sites in the original
ACRIN 6666 protocol were able to offer MRI.
SUMMARY
In summary, the cancer detection benefit to supplemental screening ultrasound seen on the
first screen persisted with each annual screen. Rates of biopsy for findings seen only on
ultrasound remained substantial on incidence screens, representing 5% of women, with only
7.4% of those women found to have cancer. Risks of false positives were lower in women
with PHBC than in women without.
As has been seen in other studies10,11,24,34, MRI significantly increased detection of early
breast cancer beyond that seen with mammography or mammography combined with
ultrasound. The 56% absolute increase in cancer detection seen in the MRI substudy (16/16
vs. 7/16) was greater than the 34% absolute increase in invasive cancer detection (71/89 vs.
41/89) seen by adding annual ultrasound to mammography in the main ACRIN 6666 study.
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However, given the low (clinically-detected) interval cancer rate of only 8% in the main
ACRIN 6666 protocol, and the fact that all interval cancers remained node-negative at
diagnosis, it is unclear that the added cost and reduced tolerability of screening MRI are
justified in women at intermediate risk for breast cancer in lieu of supplemental screening
with ultrasound. Despite its higher sensitivity, addition of screening MRI rather than
ultrasound to mammography in broader populations of women at intermediate risk with
dense breasts may not be appropriate, particularly when the current high false positive rates,
cost, and reduced tolerability of MRI are considered.
Supplementary Material
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Flowchart of protocol. Participants with negative results on both mammography and
ultrasound were imputed as having negative results on integrated reading: 1844 in year one;
1922 in year two; 1912 in year three. Reference standard was the most severe of biopsy
results within 365 days of mammographic screening and/or clinical follow-up at one year.
Biopsies prompted by an early subsequent screening examination were attributed to that
subsequent screen.
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